By Nana O 
A groundbreaking preclinical study from Weill Cornell Medicine researchers has unveiled a potentially revolutionary understanding of glioblastoma, one of the most aggressive and currently incurable forms of brain cancer. Published on April 3rd in the prestigious journal Molecular Cell, the findings propose that the intricate three-dimensional folding of DNA within the nucleus of brain cells, rather than solely gene mutations, could be the central enigma to deciphering and combating this devastating disease. This paradigm shift offers a novel perspective on cancer, moving beyond a singular focus on genetic alterations to embrace the complex spatial organization and regulatory logic of the genome.
A New Lens on an Aggressive Cancer
Glioblastoma remains a formidable challenge for oncologists and patients alike. Despite extensive research into the genetic mutations that characterize the tumor, effective therapeutic strategies to halt its relentless progression remain elusive. "Glioblastoma is one of the most aggressive and incurable tumors," stated Dr. Effie Apostolou, associate professor of molecular biology in medicine at Weill Cornell, who co-led the study. "Although we know a lot about the mutations and the genes that characterize it, we still have no effective ways to stop it. Now, we’re bringing a fresh perspective to the problem. We may have a chance of figuring out the regulatory logic of this cancer and identifying potential control centers that we can target to eliminate it."
The study’s innovative approach centers on the fundamental challenge of fitting the immense length of human DNA—estimated to be about six feet when stretched linearly—into the microscopic confines of a cell’s nucleus. This remarkable feat is accomplished through intricate multi-layered folding. The researchers’ investigation into this three-dimensional architecture revealed the existence of "hubs," specific regions within the nucleus where genetically distant segments of DNA are brought into close proximity, enabling them to communicate and cooperate in ways not apparent from their linear sequence.
Unraveling the Three-Dimensional Architecture of Cancer
In healthy brain cells, these DNA hubs are meticulously organized to orchestrate normal physiological processes, including crucial functions like embryonic development. However, when the Weill Cornell Medicine team analyzed glioblastoma cells derived from diverse patient samples, they observed a starkly different scenario. Cancer-driving genes, previously known to be implicated in glioblastoma, were found to cluster together within these hubs. More significantly, these oncogenic clusters were also found to be intricately connected with other genes that had not previously been identified as playing a direct role in glioblastoma development.
Dr. Howard Fine, the Louis and Gertrude Feil Professor of Medicine in Neurology at Weill Cornell Medicine and director of the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center, who also co-led the study, emphasized the profound implications of these findings. "This study shows that the 3D organization of DNA inside tumor cells plays a powerful role in driving brain cancer behavior — sometimes even more than mutations themselves," Dr. Fine remarked. This assertion suggests a potential re-evaluation of how genetic drivers of cancer are understood, with spatial organization emerging as a critical, and perhaps dominant, factor.
The co-first authors of the study, Dr. Sarah Breves, a surgical resident at NewYork-Presbyterian/Weill Cornell Medical Center working in Dr. Apostolou’s lab, and Dr. Dafne Campigli Di Giammartino from the Instituto Italiano di Tecnologia in Genova, Italy, played pivotal roles in the meticulous research that led to these conclusions.
3D Gene Hubs: Where Form Dictates Function
The research delved deeper into the functional significance of these 3D DNA hubs. In healthy cellular environments, the DNA regions involved in what would become cancer-related hubs in glioblastoma are typically quiescent. This means the genes within these regions are not actively transcribed into proteins that influence cellular function. This observation led the researchers to hypothesize about the consequences of disrupting these suspected cancer-related hubs.
To test this hypothesis, the team obtained glioblastoma cells from tumor samples, with the generous consent of patients undergoing treatment at NewYork-Presbyterian/Weill Cornell Medical Center. These cells were then cultured in laboratory settings. Utilizing a sophisticated gene-editing tool known as CRISPR interference, the researchers systematically silenced a specific suspected cancer-related hub within these glioblastoma cells.
The results were striking and immediate, triggering a cascade of effects. The silencing of the hub led to a significant reduction in the activity of numerous genes connected to it. Crucially, multiple known cancer-driving genes experienced disruptions in their normal function. This cellular reprogramming was further evidenced by a marked decrease in the glioblastoma cells’ ability to form tumor-like spheres, a standard in vitro model used to assess the tumorigenic potential of cancer cells. "We were able to alter the oncogenic program of glioblastoma cells and their ability to organize and form something like cancer in the dish," Dr. Apostolou explained, underscoring the direct impact of hub disruption on cancer cell behavior.
Beyond Brain Cancer: A Universal Phenomenon?
The implications of these findings extend far beyond glioblastoma. The researchers’ discovery of hyperconnected 3D hubs within glioblastoma cells prompted them to conduct a comprehensive review of previously published genomic analyses across a wide spectrum of 16 different cancer types. This broader investigation revealed that these aberrant 3D DNA hubs are not unique to brain cancer but appear to be a common feature across a majority of cancers. This includes a diverse array of malignancies such as melanoma, lung cancer, prostate cancer, and uterine cancer, among others.
While each cancer type exhibited its own unique constellation of interconnected hubs, the team also identified shared hubs that were prevalent across multiple cancer types, suggesting a common underlying mechanism or susceptibility.
Intriguingly, the study found that the formation of these hyperconnected 3D hubs is frequently not a consequence of obvious genetic mutations, such as DNA breaks, amplifications, or rearrangements. Instead, the researchers point to epigenetic changes as the primary drivers. Epigenetic alterations are modifications that affect how DNA is packaged and how genes are regulated, without altering the underlying DNA sequence itself. The study highlighted the role of the protein machinery responsible for binding to specific DNA sequences and influencing gene expression—whether a gene is turned on or off. These protein complexes, it appears, play a critical role in shaping the formation and function of these 3D DNA hubs.
Future Therapeutic Frontiers
The identification of these key control hubs within the complex 3D genomic architecture opens up entirely new avenues for therapeutic intervention. "By identifying key control hubs in this 3D structure, we’ve uncovered new potential targets for future treatments," Dr. Fine stated. He also holds the position of associate director for translational research at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.
The next phase of research, as outlined by Dr. Fine, will focus on elucidating the precise mechanisms by which these hubs form. Furthermore, the team aims to investigate whether these hubs can be safely and effectively disrupted to impede or halt tumor growth. "Our research suggests that targeting the epigenetic and spatial genome organization could complement traditional molecular therapies," he added, emphasizing the potential for a synergistic approach to cancer treatment.
Broader Implications and a Timeline of Discovery
The Weill Cornell Medicine study, published in April 2023, represents a significant leap forward in our understanding of cancer biology. While the research is preclinical, its implications are far-reaching. The shift in focus from solely gene mutations to the three-dimensional organization of the genome suggests that current diagnostic and therapeutic strategies, which primarily rely on identifying specific genetic alterations, may be incomplete.
This research could pave the way for novel diagnostic tools that assess the 3D genomic landscape of tumors, potentially offering more accurate prognoses and personalized treatment plans. The development of therapies that specifically target these 3D hubs, or the epigenetic mechanisms that regulate them, could offer a new class of treatments that are less susceptible to the development of drug resistance often seen with traditional molecular therapies.
The timeline of this research likely spans several years, beginning with initial hypotheses about DNA organization and its role in disease, followed by extensive experimental design, data collection, and rigorous analysis. The validation of findings in patient-derived glioblastoma cells, and subsequent cross-referencing with data from other cancer types, demonstrates a systematic and comprehensive approach.
While specific reactions from other institutions or patient advocacy groups are not detailed in the initial report, the findings are expected to generate significant interest and discussion within the cancer research community. Leading oncologists and geneticists will likely scrutinize the methodology and findings, potentially initiating similar lines of inquiry at other research centers. Patient advocacy groups, often at the forefront of seeking innovative treatments, will likely view these findings with cautious optimism, recognizing the long road from preclinical research to clinical application.
The study’s contribution lies in its ability to connect fundamental principles of molecular biology—DNA structure and packaging—to the complex pathology of cancer. By demonstrating that the physical arrangement of genes can profoundly influence cellular behavior and contribute to malignancy, the Weill Cornell Medicine team has opened a critical new frontier in the fight against cancer, offering a glimmer of hope for more effective treatments for diseases like glioblastoma. The future of cancer therapy may well involve not just understanding what genes are mutated, but how they are spatially orchestrated within the cellular nucleus.